KRAS and lung cancer: All in all, clinical trials investigating the efficacy of KRAS downstream inhibitors in monotherapy provided limited clinical benefit and substantial toxicity in most studies [11, 65] Yet, recent preclinical studies with patient-derived xenograft tumors highlighted the need for combination therapy in order to fully block KRAS signaling in lung cancer [89].